Navigation Links
eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008
Date:4/15/2008

SAN DIEGO, April 15 /PRNewswire/ -- Mr. Glynn has over 34 years of combined financial, operating and director level experience, and is well known within the life sciences industry for his role in the growth and development of several biotechnology companies. Most notably, Mr. Glynn retired from Invitrogen Corporation (Nasdaq: IVGN) in 2003 where, during his tenure with the company, he held several operating roles including CFO, President and COO and CEO. During this time, Mr. Glynn led the company through several stages of growth including an IPO, numerous financings and several acquisitions including Novex, GIBCO Life Technologies, Research Genetics and Molecular Probes. Mr. Glynn, following his retirement from Invitrogen Corporation, remained on the company's board of directors until April 2006.

"We are very pleased to be adding someone of Jim's reputation and experience to our board," said Todd R. Nelson Ph.D., eBioscience's Chief Executive Officer. "As an emerging global leader in the cellular analysis market, we are focused on growing our business operations through the development and commercialization of a diverse array of products, and also through the operational execution of several key strategic initiatives. In his role as director, Mr. Glynn will provide invaluable operating insight, financial advice and strategic guidance to ensure eBioscience remains a leader in the life sciences market place." Brian Seed Ph.D., Chairman of the board of directors for eBioscience added, "We look forward to tapping Jim's wealth of operating wisdom and the insights gleaned from his decades of senior management experience in the life science and related industries. Jim enjoys an enviable reputation among investors and professional fund ma
'/>"/>

SOURCE eBioscience Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
2. Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest
3. IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference
4. Sigma-Aldrich Corporation 1st Quarter 2008 Earnings Conference Call
5. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
6. Chem Rx Corporation Reports Full Year 2007 Financial Results
7. Chem Rx Corporation Postpones Conference Call to Review Full Year 2007 Financial Results
8. Genaera Corporation Announces 2007 Financial Results
9. Chem Rx Corporation Schedules Conference Call to Review Full Year 2007 Financial Results
10. Immunosyn Corporation Announces 2007 Results, Files 10KSB
11. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Dendreon Appoints Hans Bishop as Chief Operating Officer 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 3New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6
Other Biology Technology:Frost & Sullivan Recognizes Covidien for Its CT Contrast Delivery System With RFID Enabled Intelligence 2Frost & Sullivan Recognizes Covidien for Its CT Contrast Delivery System With RFID Enabled Intelligence 3Frost & Sullivan Recognizes Covidien for Its CT Contrast Delivery System With RFID Enabled Intelligence 4Trusted LASIK Surgeons Welcomes Leading Laser Expert and Inventor Jon Dishler, M.D., to Its Unique LASIK Eye Surgeon Directory for Consumers 2Trusted LASIK Surgeons Welcomes Leading Laser Expert and Inventor Jon Dishler, M.D., to Its Unique LASIK Eye Surgeon Directory for Consumers 3Trusted LASIK Surgeons Welcomes Leading Laser Expert and Inventor Jon Dishler, M.D., to Its Unique LASIK Eye Surgeon Directory for Consumers 4Trusted LASIK Surgeons Welcomes Leading Laser Expert and Inventor Jon Dishler, M.D., to Its Unique LASIK Eye Surgeon Directory for Consumers 5Trusted LASIK Surgeons Welcomes Leading Laser Expert and Inventor Jon Dishler, M.D., to Its Unique LASIK Eye Surgeon Directory for Consumers 6Trusted LASIK Surgeons Welcomes Leading Laser Expert and Inventor Jon Dishler, M.D., to Its Unique LASIK Eye Surgeon Directory for Consumers 7Trusted LASIK Surgeons Welcomes Leading Laser Expert and Inventor Jon Dishler, M.D., to Its Unique LASIK Eye Surgeon Directory for Consumers 8Pharmaxis Appoints French Distributor for Aridol(TM) 2
Breaking Biology News(10 mins):Charles Darwin: More than the origin 2Charles Darwin: More than the origin 3More than fish bait: Worms unlock secrets to new epilepsy treatments 2Are Microbes Headed Back to School this Fall 3F 53556 1Are Microbes Headed Back to School this Fall 3F 53556 2Amgen Announces Positive Top Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa 2 4817 1Amgen Announces Positive Top Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa 2 4817 2Amgen Announces Positive Top Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa 2 4817 3Amgen Announces Positive Top Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa 2 4817 4Amgen Announces Positive Top Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa 2 4817 5Amgen Announces Positive Top Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa 2 4817 6Amgen Announces Positive Top Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa 2 4817 7Amgen Announces Positive Top Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa 2 4817 8Surgical Masks Help Ward Off Flu Maybe 53553 1Surgical Masks Help Ward Off Flu Maybe 53553 2Surgical Masks Help Ward Off Flu Maybe 53553 3Surgical Masks Help Ward Off Flu Maybe 53553 4